- Conditions
- Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
- Interventions
- RGN-137, Placebo
- Drug
- Lead sponsor
- Lenus Therapeutics, LLC
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 53
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Prademagene Zamikeracel
- Combination Product
- Lead sponsor
- Abeona Therapeutics, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2045
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 1 more
- Conditions
- Epidermolysis Bullosa
- Interventions
- Palifermin, Fludarabine, Busulfan, Lorazepam, Alemtuzumab, Tacrolimus
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Chicago, Illinois • New York, New York
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Gentamicin Sulfate
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- Not listed
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Granulocyte Colony Stimulating Factor (GCSF)
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Squamous Cell Carcinoma
- Interventions
- BVEC
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- Not listed
- Lead sponsor
- Lotus Tissue Repair, Inc.
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
- Interventions
- TCP-25 gel, Vehicle (placebo)
- Drug
- Lead sponsor
- Xinnate AB
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- EB-101
- Biological
- Lead sponsor
- Abeona Therapeutics, Inc
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Redwood City, California • Worcester, Massachusetts
- Conditions
- Epidermolysis Bullosa
- Interventions
- APR-TD011
- Combination Product
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Interventions
- Topical Beremagene Geperpavec, Placebo
- Biological · Other
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Rancho Santa Margarita, California • Stanford, California • Coral Gables, Florida
- Conditions
- Epidermolysis Bullosa Dystrophica
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans
- Interventions
- Not listed
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Epidermolysis Bullosa Dystrophica
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2029
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Epidermolysis Bullosa (EB), Epidermolysis Bullosa Simplex, Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
- Interventions
- Diacerein 1% Ointment
- Drug
- Lead sponsor
- Castle Creek Pharmaceuticals, LLC
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Chicago, Illinois • Chapel Hill, North Carolina
- Conditions
- Epidermolysis Bullosa
- Interventions
- SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
- Drug
- Lead sponsor
- Scioderm, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
- Conditions
- Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB
- Interventions
- EB-101 Surgical application of RDEB wounds
- Biological
- Lead sponsor
- Abeona Therapeutics, Inc
- Industry
- Eligibility
- 12 Months and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Redwood City, California • Worcester, Massachusetts
- Conditions
- Epidermolysis Bullosa
- Interventions
- SD-101-6.0 cream, Placebo (SD-101-0.0) cream
- Drug
- Lead sponsor
- Scioderm, Inc.
- Industry
- Eligibility
- 1 Month and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 17 more
- Conditions
- Epidermolysis Bullosa, Healthy, Genetic Skin Disease, Epidermolysis Bullosa Simplex, Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica
- Interventions
- Experimental Group
- Procedure
- Lead sponsor
- Joyce Teng
- Other
- Eligibility
- 0 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Epidermolysis Bullosa Dystrophica
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Gentamicin
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa
- Interventions
- Not listed
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Dystrophic Epidermolysis Bullosa
- Interventions
- ALLO-ASC-SHEET, Vehicle Control
- Biological · Other
- Lead sponsor
- Anterogen Co., Ltd.
- Industry
- Eligibility
- 4 Years to 60 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Epidermolysis Bullosa Dystrophica, Recessive
- Interventions
- FCX-007
- Genetic
- Lead sponsor
- Castle Creek Biosciences, LLC.
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 2
- States / cities
- Stanford, California • Aurora, Colorado